Our mission is to revolutionize knowledge of Alzheimer’s disease.
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD) was the first stage of a precompetitive partnership among government, industry and nonprofit organizations that focused on discovering novel, clinically relevant therapeutic targets, and on developing biomarkers to help validate existing therapeutic targets for Alzheimer’s disease.
This multisector partnership, managed by the Foundation for the NIH from 2014-2022, focused on providing a data-driven approach for identification and validation of biomarkers and disease-relevant targets that will lead to increased clinical trial success.
A Public Health Crisis
Alzheimer’s disease is a type of dementia that affects the brain, particularly areas related to memory, thinking, and behavior. It is a progressive condition, which means that symptoms worsen over time, and is projected to affect approximately 14 million people by the year 2060.
Alzheimer’s disease is caused by the buildup of abnormal protein clumps and tangles in the brain, which damage and eventually kill brain cells. In the early stages of Alzheimer’s, a person may experience forgetfulness and difficulty with planning or problem-solving. This leads to a progressive loss of cognitive functions, and symptoms worsen and interfere with daily life and activities.
Deeper Understanding of Disease Drivers
Alzheimer’s disease drug candidates have had a high failure rate in end-stage clinical trials. Developing a deeper understanding of the disease drivers is crucial to the success of these trials. AMP AD has made significant contributions to this effort through a large project focused on target discovery and preclinical validation. By integrating and sharing the analysis of large-scale molecular data from human brain samples, AMP AD rapidly identified novel therapeutic targets.
In addition, AMP AD has identified biomarkers that could be used to track responsiveness to treatment and/or disease progression. This includes exploring the utility of tau imaging and novel fluid biomarkers. These findings could potentially improve diagnosis, aid in the development of new therapies, and ultimately improve outcomes for those affected by Alzheimer’s disease. These efforts continue through the AMP AD 2.0 project.
Private Sector Partners
Public Sector Partners
AMP AD Knowledge Portal
Discover and download Alzheimer’s disease data, analyses, and tools from AMP AD.Learn More
AMP AD Agora Platform
Agora is an open-source platform, created to provide curated AMP AD verified systems biology analyses showing which genes are associated with Alzheimer’s disease.Learn More